The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

GI Cancers MORE >>

Comparable efficacy and minimized adverse events were seen with a lower dose of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in elderly and frail patients with advanced gastroesophageal cancer, according to findings to be presented during the 2019 American Society of Clinical Oncology Annual Meeting.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.